Benzinga | Jun 22, 2021 08:10AM EDT

Soligenix Shares Up Pre Market Following Earlier Co. Press Release Highlighting Pivotal Phase 3 FLASH Study Selected For Presentation At US Cutaneous Lymphoma Consortium Annual Meeting Jun. 26

Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the University of Pennsylvania, and the Lead Principal Investigator for the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study in cutaneous T-cell lymphoma (CTCL), will present key details of HyBryte(tm) (hypericin ointment 0.25%) efficacy and safety profile demonstrated in the FLASH study at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting, to be held on June 26, 2021. Dr. Kim plans to detail the success of HyBryte(tm) in the broad CTCL patient population, as well as the safety and tolerability of HyBryte(tm), and to compare the data from the study to the currently available treatment options. The FLASH trial is the largest multicenter, randomized, double-blind, placebo-controlled, skin-directed therapy study in CTCL to date, enrolling a total of 169 patients.

Oral Presentation:

Topical hypericin ointment photodynamic therapy is effective and safe in CTCL (FLASH study)Dr. Kim's presentation will be given during the 11:15 am - 12:15 pm Eastern Time session on June 26, 2021. Only registered attendees can view and participate in this virtual conference. Attendees can register for United States Cutaneous Lymphoma Consortium.

"The audience at the USCLC consists of key disease state experts and potential future prescribers of this novel photodynamic therapy assuming it is approved for distribution, many of whom were investigators with me in this pivotal Phase 3 clinical trial. I am very excited to meet with them to share and analyze our data together," noted Dr. Kim. "To be selected to present our data at this forum is a great opportunity, as I believe HyBryte(tm) can better meet the therapeutic needs of patients with CTCL where additional treatment options are desperately needed. I would like to thank all site investigators, and especially our patients, for their contributions to developing this promising new therapy."